Pharming Group (NASDAQ:PHAR - Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $8.54, but opened at $9.06. Pharming Group shares last traded at $9.15, with a volume of 969 shares trading hands.
Analyst Ratings Changes
PHAR has been the subject of several research reports. HC Wainwright restated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research note on Tuesday, December 17th. Jefferies Financial Group initiated coverage on Pharming Group in a research note on Monday, December 9th. They issued a "buy" rating and a $14.00 target price for the company.
Check Out Our Latest Stock Analysis on Pharming Group
Pharming Group Price Performance
The firm has a market cap of $593.91 million, a price-to-earnings ratio of -33.58 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The business has a 50 day simple moving average of $9.29 and a 200-day simple moving average of $8.56.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,997 shares of the company's stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
